Icure Pharmaceutical Incorporation아이큐어
175250 · KOSDAQ · ₩175250 · 아이큐어
₩1,530▲ ₩159 (11.60%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩83B | ₩69B | ₩57B | ₩59B | ₩64B |
| Cost of sales | ₩79B | ₩62B | ₩56B | ₩65B | ₩69B |
| Gross profit | ₩4.4B | ₩7.6B | ₩1.3B | −₩5.6B | −₩4.7B |
| Operating income | −₩12B | −₩17B | −₩23B | −₩27B | −₩28B |
| Net income | −₩35B | ₩25M | −₩32B | −₩43B | −₩38B |
| Net income to shareholders | −₩34B | ₩1B | −₩31B | −₩42B | −₩38B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩90B | ₩133B | ₩166B | ₩224B | ₩215B |
| Current assets | ₩34B | ₩55B | ₩32B | ₩81B | ₩59B |
| Cash and equivalents | ₩8.3B | ₩17B | ₩6.3B | ₩51B | ₩18B |
| Total liabilities | ₩66B | ₩72B | ₩107B | ₩132B | ₩117B |
| Current liabilities | ₩59B | ₩65B | ₩95B | ₩110B | ₩55B |
| Borrowings | ₩25B | ₩41B | ₩76B | ₩87B | ₩74B |
| Total equity | ₩24B | ₩61B | ₩60B | ₩92B | ₩99B |
| Shareholders' equity | ₩26B | ₩60B | ₩58B | ₩90B | ₩96B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩2.7B | −₩17B | −₩14B | −₩11B | −₩26B |
| Capital spending | ₩5.1B | ₩2B | ₩2.2B | ₩4.2B | ₩5.7B |
| Free cash flow | −₩7.8B | −₩19B | −₩16B | −₩15B | −₩32B |
Consolidated where available. Amounts in won.
Also known as: Icure Pharmaceutical Incorporation / 아이큐어 / 175250 / KRX:175250
Source: KRX statistical information